Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, "real world" registry

Journal of Invasive Cardiology

Volumn 16, Issue 6, 2004, Pages 304-310

  Gupta, Vishal ^b   Aravamuthan, Bhooma R ^b   Baskerville, Susan ^b   Smith, Susan K ^b   Gupta, Vijaya ^b   Lauer, Michael A ^b   Fischell, Tim A ^a  

^a Borgess Heart Institute   (United States)

^b NONE

Author keywords

Angioplasty; Biocompatible; Blood vessel prosthesis implantation; Coated materials; Complications; Percutaneous transluminal coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ACUTE DISEASE; ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; REGISTER; SUBACUTE STENT THROMBOSIS; SUDDEN DEATH; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY VESSELS; FEMALE; HEPARIN; HUMANS; INCIDENCE; MALE; MICHIGAN; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGISTRIES; STENTS; SURVIVAL RATE; THROMBOSIS;

EID: 2642558698     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Serruys PW, Di Mario C. Who was thrombogenic: The stent or the doctor? Circulation 1995;91:1891-1893.
2. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: Evolving issues and current concepts. J Am Coll Cardiol 1996;27:494-503.
3. Benzuly KH, ONeill WW, Gangadharan V, et al. Stenting in acute myocardial infarction (STAMI): Bailout, conditional and planned stents. J Am Coll Cardiol 1997;29:456A.
4. De Scheerder I, Wang K, Wilczek K, et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997;95:1549-1553.
5. Leatham EW, Bath PM, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995;73:10-13.
6. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
7. Fuster V, Lewis A. Conner memorial lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994;90:2126-2146.
8. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
9. Neumann FJ, Gawaz M, Ott I, et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996;27:15-21.
10. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis: Early versus late stent thrombosis in the stent era. Cathet Cardiovasc Interv 2002;55:142-147.
11. Silva JA, Ramee SR, White CJ, et al. Primary stenting in acute myocardial infarction: Influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999;138:446-455.
12. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: Analysis of a single center registry. J Am Coll Cardiol 2002;40:1567-1572.
13. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-1603.
14. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
15. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.
16. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084-1089.
17. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.
18. Serruys PW, Unger F, van Hout BA, et al. The ARTS (Arterial Revascularization Therapies Study). Semin Interv Cardiol 1999;4:209-219.
19. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT Study Group. N Engl J Med 1994;331:489-495.
20. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Investigators. Lancet 1998;352:87-92.
21. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
22. Batchelor WB, Mahaffey KW, Berger PB, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial. J Am Coll Cardiol 2001;38:1608-1613.
23. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519-1527.
24. Reynolds MR, Rinaldi MJ, Pinto DS, Cohen DJ. Current clinical characteristics and economic impact of subacute stent thrombosis. J Invas Cardiol 2002;14:364-368.
25. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12.
26. Moussa I, Di Mario C, Di Francesco L, et al. Subacute stent thrombosis and the anticoagulation controversy: Changes in drug therapy, operator technique and the impact of intravascular ultrasound. Am J Cardiol 1996;78:13-17.
27. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the BENESTENT-II Pilot Study. Circulation 1996;93:412-422.
28. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet 1998;352:673-681.
29. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341:1949-1956.
30. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: The Total Occlusion Study of Canada (TOSCA), Circulation 1999;100:236-242.
31. Vrolix MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000;86:385-389.
32. Lotan C, Kranjec I, Holmer E, et al. Use of heparin-coated stents to reduce subacute stent thrombosis in complex lesions: Results from the multicenter internet-based HEPANET registry. Am J Cardiol 2002;88:13-16.
33. Dangas G, Mehran R, Abizaid AS, et al. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol 2001;87:470-472, A7.
34. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
35. Calver AL, Blows LJ, Harmer S, et al. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am Heart J 2000;140:483-491.
36. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001;104:539-543.
37. Muller MM, Hackl W, Griesmacher A. Point-of-care testing - The intensive care laboratory. Anaesthesist 1999;48:3-8.
38. Blackburn H, Keys A, Simonson E, et al. The electrocardiogram in population studies. A classification system. Circulation 1960;21:1160-1175.
39. SAS Institute Inc. The SAS System for Windows V8. Release 8.00 TS Level 00M0. Cary, North Carolina, USA: 1999.
40. Hardhammar PA, van Beusekom HM, Emanuelsson HU, et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996;93:423-430.
41. Ahn YK, Jeong MH, Kim JW, et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Cathet Cardiovasc Interv 1999;48:324-330.
42. Haude M, Konorza TF, Kalnins U, et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003;107:1265-1270.
43. Ruygrok PN, Sim KH, Chan C, et al. Coronary intervention with a heparin-coated stent and aspirin only. J Invas Cardiol 2003;15:439-441.
44. Mehran R, Aymong ED, Ashby DT, et al. Safety of aspirin-alone regimen after intracoronary stenting with a heparin-coated stent. Final results of the HOPE (Hepacoat and an antithrombotic regimen of aspirin alone) Study. Circulation 2003;108:1078-1088.